Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company and a leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. ET in New York City.
Help employers find you! Check out all the jobs and post your resume.